506414
Fermenta Biotec. share price & financials
- Price
- ₹339
- Market cap
- ₹1.4k Cr
- Sector
- Healthcare
What Fermenta Biotec. does
Fermenta Biotech manufactures Vitamin D3 for both human (pharmaceutical, nutraceutical, food-fortification) and animal/feed applications, alongside pharmaceutical APIs and intermediates, enzyme-based green-chemistry products, biotechnology-based environmental remediation solutions, and food items such as Fortified Rice Kernels (FRK) and customized vitamin/mineral premixes. It runs manufacturing and R&D facilities across India (Thane, Kullu, Dahej, Tirupati) and has a toll-manufacturing collaboration in Germany, supplying over 400 customers across 60+ countries in the pharmaceutical, dietary-supplement, food & beverage, veterinary and animal-feed industries.
Segments
- Nutrition (Vitamin D3 - Human)
- Nutrition (Vitamin D3 - Animal)
- Nutrition (Others)
- API & Intermediates
- Green Chemistry / Enzymes
- Environmental Solutions
- Manufacturing & R&D facilities
- 4 in India (Thane HQ+R&D, Kullu, Dahej, Tirupati) plus a toll-manufacturing collaboration in Germany
- Global Vitamin D3 ranking
- Among the world's top 3 manufacturers of Vitamin D3
- Employees
- 600+
- Global customers
- 400+ across 60+ countries
- Scientists & engineers
- 100+
- Global regulatory certifications
- 15+ (incl. EU GMP, WHO-GMP, USFDA, FSSC, HALAL, KOSHER, GAIN)
Quarterly results
Q1 FY27: revenue down 10.6%, net profit down 55.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 95 | 156 | 140 | 136 | 130 +37% | 137 −12% | 122 −13% | 122 −11% |
| EBITDA | 19 | 53 | 37 | 28 | 27 +42% | 25 −53% | 20 −46% | 18 −36% |
| Net profit | 11 | 38 | 33 | 22 | 18 +62% | 12 −68% | 19 −44% | 10 −56% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +35.0% 1Y
1Y: ₹351.85 on 10 Sept 2025 → ₹475.05. High ₹559.55 (7 Aug 2026), low ₹262.85 (29 Oct 2025).
Financials, as filed
Revenue grew 14.5% a year over 3 years, FY23 to FY26. Operating margin widened to 19.0%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹350 Cr | ₹336 Cr | ₹469 Cr | ₹525 Cr |
| Operating profit | ₹17 Cr | ₹28 Cr | ₹110 Cr | ₹100 Cr |
| Operating margin | 4.9% | 8.2% | 23.4% | 19.0% |
| Interest | ₹20 Cr | ₹17 Cr | ₹14 Cr | ₹12 Cr |
| Depreciation | ₹28 Cr | ₹25 Cr | ₹24 Cr | ₹22 Cr |
| Net profit | ₹-54 Cr | ₹-24 Cr | ₹76 Cr | ₹70 Cr |
| Net margin | -15.4% | -7.2% | 16.3% | 13.4% |
| Cash from operations | ₹116 Cr | ₹105 Cr | ₹41 Cr | ₹93 Cr |
| Free cash flow | ₹76 Cr | ₹86 Cr | ₹38 Cr | ₹63 Cr |
| ROCE | 0.0% | 3.0% | 23.0% | 21.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹15 Cr | ₹14 Cr |
| Reserves | ₹346 Cr | ₹358 Cr | ₹301 Cr | ₹274 Cr | ₹376 Cr | ₹392 Cr |
| Borrowings | ₹232 Cr | ₹239 Cr | ₹220 Cr | ₹139 Cr | ₹112 Cr | ₹113 Cr |
| Other liabilities | ₹94 Cr | ₹96 Cr | ₹102 Cr | ₹120 Cr | ₹149 Cr | ₹128 Cr |
| Total liabilities | ₹687 Cr | ₹707 Cr | ₹637 Cr | ₹548 Cr | ₹651 Cr | ₹648 Cr |
| Fixed assets | ₹263 Cr | ₹299 Cr | ₹267 Cr | ₹269 Cr | ₹219 Cr | ₹220 Cr |
| Capital work in progress | ₹57 Cr | ₹35 Cr | ₹45 Cr | ₹2 Cr | ₹26 Cr | ₹13 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹367 Cr | ₹373 Cr | ₹321 Cr | ₹277 Cr | ₹406 Cr | ₹414 Cr |
| Total assets | ₹687 Cr | ₹707 Cr | ₹637 Cr | ₹548 Cr | ₹651 Cr | ₹648 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Aug 2026
Since Sep 2025, the public trimmed −1.80 pp while others added +1.41 pp. The shareholder count grew 7% to 14,777.
- Promoters
- 64.1%
- FIIs
- 0.4%
- DIIs
- 0.0%
- Public
- 33.0%
- Others
- 2.5%
Since Sep 2025
- Public −1.80 pp
- Others +1.41 pp
- FIIs +0.35 pp
How it drifted, 12 quarters
Over this window the public fell from 36.0% to 33.0% — −3.1 pp.
Ownership split by quarter, oldest first. Dec '23: Promoters 62.1%, Public 36.0%, Others 1.9%.Mar '24: Promoters 62.1%, Public 36.0%, Others 1.9%.Jun '24: Promoters 62.1%, Public 36.1%, Others 1.8%.Sep '24: Promoters 62.1%, FIIs 0.1%, Public 36.4%, Others 1.5%.Dec '24: Promoters 62.1%, FIIs 0.0%, Public 37.0%, Others 0.9%.Mar '25: Promoters 64.1%, FIIs 0.0%, Public 35.0%, Others 0.9%.Jun '25: Promoters 64.1%, FIIs 0.0%, Public 35.0%, Others 0.9%.Sep '25: Promoters 64.1%, FIIs 0.0%, Public 34.8%, Others 1.1%.Dec '25: Promoters 64.1%, FIIs 0.0%, Public 34.0%, Others 1.9%.Mar '26: Promoters 64.1%, FIIs 0.0%, Public 33.3%, Others 2.6%.Jun '26: Promoters 64.1%, FIIs 0.1%, DIIs 0.0%, Public 33.2%, Others 2.5%.Aug '26: Promoters 64.1%, FIIs 0.4%, DIIs 0.0%, Public 33.0%, Others 2.5%.
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Investor Education and Protection Fund (IEPF) newly disclosed 0.60% held
- Unclaimed or Suspense or Escrow Account newly disclosed 0.16% held
- Independent Director or his relatives newly disclosed 0.02% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Aug 2026 filing
Every holder of Fermenta Biotec. above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| Krishna Datla | 36.04% | unchanged |
| Satish Varma Azad Nadimpally | 11.73% | unchanged |
| Anupama Datla Desai | 8.70% | unchanged |
| Preeti Thakkar | 7.61% | unchanged |
| Rakesh Kantilal Shah | 1.72% | unchanged |
| Krishan Premnarayen | 1.38% | unchanged |
| Investor Education and Protection Fund (IEPF) | 0.60% | newly disclosed |
| Unclaimed or Suspense or Escrow Account | 0.16% | newly disclosed |
| Independent Director or his relatives | 0.02% | newly disclosed |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Fermenta Biotec.
Guides on how to read this kind of business and the numbers that matter.